ClinicalTrials.gg
TerminatedNCT00640549ALPINUpdated Feb 18, 2021

Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus

A Phase 4 interventional study of Atorvastatin and Placebo in Hyperlipidemia, Diabetes Mellitus, Type 2 and Non-Insulin Dependent Diabetes Mellitus, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 14 sites in Germany. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies testing atorvastatin in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Atorvastatin · Hyperlipidemias.

Enrollment
28th of 37
41 · median 99
Started
2003
with 3 others
Phase 4
10 of 37
none open now
Registered
14th of 37
by date
Lead sponsor
4 of 37
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 37 studies testing atorvastatin in Hyperlipidemias, this one is the 28th largest by enrollment, is one of 4 that started in 2003, is one of 10 in phase 4, and was the 14th registered.

Hyperlipidemias

863 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 37 studies testing atorvastatin in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 37 studies testing atorvastatin in Hyperlipidemias as a file.
02

Study summary

The study will investigate the effects of atorvastatin on the concentrations of small, dense LDL and HDL subfractions in patients with diabetes and the underlying mechanisms of these effects.

Read the detailed description

This study was terminated on October 6, 2004. The study terminated prematurely because of a higher screening failure rate than expected. There were no safety or efficacy reasons involved in the decision to terminate.

03

Conditions studied

  • Hyperlipidemia
  • Diabetes Mellitus, Type 2
  • Non-Insulin Dependent Diabetes Mellitus

Keywords

  • LDL-subfractions, HDL-subfractions, non insulin dependent diabetes mellitus (NIDDM), hyperlipidemia, atorvastatin
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with a diagnosis of type 2 diabetes mellitus who either have never had a major adverse cardiac event (MACE) diagnosed before or who had a MACE diagnosed at least 6 months ago, but who, according to the judgement of the treating general practitioner, do not receive any hyperlipidemic therapy. Major adverse cardiac events (MACE) include myocardial infarction, coronary angioplasty, coronary artery bypass graft or other revascularization procedures.

At Screening:

Visit 1 (week -4):

  1. Male patients aged >35 and ≤75 years and female patients ≤75 years with a diagnosis of type 2 diabetes mellitus
  2. Patients have been euthyroid for at least six months
  3. Written obtained

    At Visit 2 (week 0):

  4. LDL cholesterol ≥130 mg/dl (3.3 mmol/l ) and \<190 mg/dl (4.9 mmol/l)
  5. Triglycerides \<150 mg/dl (1.69 mmol/l ) and \<600 mg/dl (11.3 mmol/l)
  6. Sum of LDL-5 and LDL-6 cholesterol ≥25 mg/dl (0.65 mmol/l)
  7. Follicle stimulating Hormone (FSH) >30 U/l in female patients aged \<60 years or FSH >20 U/l in female patients aged ≥60 years

Exclusion criteria

Exclusion Criteria:

  • > 8.0
  • Creatine kinase (CK) >5 times the
  • Patients having taken lipid lowering medication within 8 weeks of the screening visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Placebo comparator
    2

    Drug: Placebo

  • Active comparator
    1

    Drug: Atorvastatin

Interventions

  • After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.

    Also known as: Lipitor, Sortis

  • DrugPlacebo

    After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Changes in concentration of HDL subfractions 2a and 2b compared with screening (visit 1)

    Time frame: 8 weeks (visit 4)

  2. Changes in concentration of LDL subfractions LDL-5 and LDL-6 compared with screening (visit 1)

    Time frame: 8 weeks (visit 4)

Secondary outcomes

  1. Changes in concentration of apolipoprotein B in VLDL, IDL, LDL-1 through LDL-6 and apolipoprotein A I in HDL subfractions 2a, 2b, and HDL-3 compared with screening (visit 1)

    Time frame: 8 weeks (visit 4)

  2. Changes in Cholesterol ester transfer protein (CETP), lipoprotein and hepatic lipase activity compared with screening (visit 1)

    Time frame: 8 weeks (visit 4)

  3. Changes in concentration of triglycerides, LDL, and HDL compared with screening (visit 1)

    Time frame: 8 weeks (visit 4)

  4. Changes in size of LDL subfractions compared with screening (visit 1)

    Time frame: 8 weeks (visit 4)

07

Study locations

14 sites
  • Pfizer Investigational Site
    BAD Muenster AM Stein, 55583, Germany
  • Pfizer Investigational Site
    Bosenheim, 55545, Germany
  • Pfizer Investigational Site
    Bretten, 75015, Germany
  • Pfizer Investigational Site
    Dresden, 01307, Germany
  • Pfizer Investigational Site
    Duisburg, 47199, Germany
  • Pfizer Investigational Site
    Essen, 45217, Germany
  • Pfizer Investigational Site
    Goch, 47574, Germany
  • Pfizer Investigational Site
    Heidelberg, 69120, Germany
  • Pfizer Investigational Site
    Kuenzing, 94550, Germany
  • Pfizer Investigational Site
    Offenbach, 63067, Germany
  • Pfizer Investigational Site
    Offenbach, 63071, Germany
  • Pfizer Investigational Site
    Offenbach, 63073, Germany
  • Pfizer Investigational Site
    Rain, 94369, Germany
  • Pfizer Investigational Site
    Schwabenheim, 55270, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2008
First posted
Mar 21, 2008
Start
Mar 2003
CompletionActual
Oct 2004
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00640549
Responsible party
Sponsor
First posted
Mar 21, 2008
Start date
Mar 2003
Completion
Oct 2004
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion